Dement Neurocogn Disord.  2012 Jun;11(2):29-37. 10.12779/dnd.2012.11.2.29.

Activities of Daily Living and Dementia

• Yang Y
• Yang HD
• Hong YJ
• Kim JE
• Park MH
• Na HR
• Han IW
• Kim S

• KMID: 2172232
• DOI: http://doi.org/10.12779/dnd.2012.11.2.29

Abstract

Activities of daily living (ADL) refer to the ability to care for self and perform daily activities within an individual's place or in outdoor environments. ADL comprise two main categories: Basic or physical ADL and Instrumental ADL. The latter allows for the earlier detection of functional decline than the former. The cognitive changes in neurodegenerative dementias contribute to the impaired ability of the patients to take care of themselves. Activities of daily living is a major criterion for diagnosing dementia. Furthermore, it has recently been emphasized that some impairment of activities of daily living, particularly of complex instrumental functions, is already present even in mild cognitive impairment prodromal stage of dementia, although mild cognitive impairment is distinguished from dementia by the absence of significant deficit in activities of daily living. The impaired activities of daily living increase the rate of institutionalization of the patients with dementia to nursing home and inevitably bring about the changes in the qualities of life not only of the patients but their caregivers. One of the best ways to evaluate the degree of impairment in activities of daily living and the care burden is through standardized functional assessment tools according to the severity of dementia. These tools provide objective data, thereby allowing the clinicians to judge decline and improvement in the functional status and to plan individualized care. In this review, we will review the clinical significance of evaluating ADL, the assessment tools according to the severity of dementia, and therapeutic approaches to enhance the functional levels. We will also review the impact of the impaired ADL on the quality of life among the patients and their care providers.

Keyword

Activities of daily living; Dementia; Caregiver

MeSH Terms

Activities of Daily Living
Caregivers
Dementia
Humans
Hypogonadism
Institutionalization
Mild Cognitive Impairment
Mitochondrial Diseases
Nursing Homes
Ophthalmoplegia
Prodromal Symptoms
Quality of Life
Hypogonadism
Mitochondrial Diseases
Ophthalmoplegia

Reference

1. Korean Dementia Association. Dementia A Clinical Approach. 2011. 2nd ed. Anyang: Academya.

2. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. Md State Med J. 1965. 14:61–65.

3. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969. 9:179–186.

4. Sikkes SA, et al. A systematic review of Instrumental Activities of Daily Living scales in dementia: room for improvement. J Neurol Neurosurg Psychiatry. 2009. 80:7–12.

5. Gold DA. An examination of instrumental activities of daily living assessment in older adults and mild cognitive impairment. J Clin Exp Neuropsychol. 2012. 34:11–34.

6. Desai AK, Grossberg GT, Sheth DN. Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment. CNS Drugs. 2004. 18:853–875.

7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (Text Revision). 2000. 4th ed. Washington DC: American Psychiatric Association.

8. Royall DR, et al. The cognitive correlates of functional status: a review from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci. 2007. 19:249–265.

9. Aretouli E, Brandt J. Everyday functioning in mild cognitive impairment and its relationship with executive cognition. Int J Geriatr Psychiatry. 2010. 25:224–233.

10. Rubin EH, Morris JC, Grant EA, Vendegna T. Very mild senile dementia of the Alzheimer type. I. Clinical assessment. Arch Neurol. 1989. 46:379–382.

11. Juva K, Makela M, Erkinjuntti T, Sulkava R. Functional assessment scales in detecting dementia. Age Ageing. 1997. 26:393–400.

12. Monaci L, Morris RG. Neuropsychological screening performance and the association with activities of daily living and instrumental activities of daily living in dementia: baseline and 18- to 24-month follow-up. Int J Geriatr Psychiatry. 2012. 27:197–204.

13. Pérès K, Chrysostome V, Fabrigoule C, Orgogozo JM, Dartigues JF, Barberger-Gateau P. Restriction in complex activities of daily living in MCI: impact on outcome. Neurology. 2006. 67:461–466.

14. Peres K, Helmer C, Amieva H. Natural history of decline in instrumental activities of daily living performance over the 10 years preceding the clinical diagnosis of dementia: a prospective population-based study. J Am Geriatr Soc. 2008. 56:37–44.

15. Schmitter-Edgecombe M, Woo E, Greeley DR. Characterizing Multiple Memory Deficits and Their Relation to Everyday Functioning in Individuals With Mild Cognitive Impairment. Neuropsychology. 2009. 23:168–177.

16. Daly E, Zaitchik D, Copeland M, Schmahmann J, Gunther J, Albert M. Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol. 2000. 57:675–680.

17. Barberger-Gateau P, Fabrigoule C, Rouch I, Letenneur L, Dartigues JF. Neuropsychological correlates of self-reported performance in instrumental activities of daily living and prediction of dementia. J Gerontol B Psychol Sci Soc Sci. 1999. 54:P293–P303.

18. Thal LJ, Grundman M, Klauber MR. Dementia: characteristics of a referral population and factors associated with progression. Neurology. 1988. 38:1083–1090.

19. Galasko D, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997. 11:Suppl 2. S33–S39.

20. Gauthier S, et al. Outcome measures for the study of activities of daily living in vascular dementia. Alzheimer Dis Assoc Disord. 1999. 13:Suppl 3. S143–S147.

21. Mohr E, Feldman H, Gauthier S. Canadian guidelines for the development of antidementia therapies: a conceptual summary. Can J Neurol Sci. 1995. 22:62–71.

22. Bavazzano A, et al. Functional evaluation of Alzheimer patients during clinical trials: A review. Arch Gerontol Geriatr. 1998. 26:suppl 6. 27–32.

23. Cotrell V, Schulz R. The perspective of the patient with Alzheimer's disease: a neglected dimension of dementia research. Gerontologist. 1993. 33:205–211.

24. Ballard CG, et al. The prevalence, assessment and associations of falls in dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord. 1999. 10:97–103.

25. Garand L, et al. Caregiving burden and psychiatric morbidity in spouses of persons with mild cognitive impairment. Int J Geriatr Psychiatry. 2005. 20:512–522.

26. Ewbank DC. Deaths attributable to Alzheimer's disease in the United States. Am J Public Health. 1999. 89:90–92.

27. Newman SC, Bland RC. Canadian trends in mortality from mental disorders, 1965-1983. Acta Psychiatr Scand. 1987. 76:1–7.

28. Noale M, et al. Dementia and disability: impact on mortality. The Italian Longitudinal Study on Aging. Dement Geriatr Cogn Disord. 2003. 16:7–14.

29. Ferrucci L, Guralnik JM, Pahor M, Corti MC, Havlik RJ. Hospital diagnoses, Medicare charges, and nursing home admissions in the year when older persons become severely disabled. JAMA. 1997. 277:728–734.

30. Häkkinen A, Heinonen M, Kautiainen H, Huusko T, Sulkava R, Karppi P. Effect of cognitive impairment on basic activities of daily living in hip fracture patients: a 1-year follow-up. Aging Clin Exp Res. 2007. 19:139–144.

31. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ. Group AsDCS. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005. 352:2379–2388.

32. Cotrell V, Schulz R. The perspective of the patient with Alzheimer's disease: a neglected dimension of dementia research. Gerontologist. 1993. 33:205–211.

33. León-Salas B, Olazarán J, Muñiz R, González-Salvador MT, Martínez-Martín P. Caregivers' estimation of patients' quality of life (QoL) in Alzheimer's disease (AD): an approach using the ADRQL. Arch Gerontol Geriatr. 2011. 53:13–18.

34. Bracco L, Gallato R, Grigoletto F, Lippi A, Lepore V, Bino G, Lazzaro MP, Carella F, Piccolo T, Pozzilli C. Factors affecting course and survival in Alzheimer's disease. A 9-year longitudinal study. Arch Neurol. 1994. 51:1213–1219.

35. Gauthier S, Rockwood K, Gélinas I, Sykes L, Teunisse S, Orgogozo JM, Erkinjuntti T, Erzigkeit H, Gleeson M, Kittner B, Pontecorvo M, Feldman H, Whitehouse P. Outcome measures for the study of activities of daily living in vascular dementia. Alzheimer Dis Assoc Disord. 1994. 13:Suppl 3. S143–S147.

36. Graf C. The Lawton instrumental activities of daily living scale. Am J Nurs. 2008. 108:52–62. quiz 62-53.

37. Canadian Study of Health and Aging Working Group. Patterns of caring for people with dementia in Canada. Can J Aging. 1994. 13:470–487.

38. Desai AK, Grossberg GT, Sheth DN. Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment. CNS Drugs. 2004. 18:853–875.

39. Feldman HH, Schmitt FA, Olin JT. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord. 2006. 20:263–268.

40. Suh GH, Ju YS, Yeon BK, Shah A. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline. Int J Geriatr Psychiatry. 2004. 19:817–824.

41. Olazaran J, Reisberg B, Clare L, Cruz I, Pena-Casanova J, Del Ser T, et al. Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy. Dement Geriatr Cogn Disord. 2010. 30:161–178.

42. Galasko D, Kershaw PR, Schneider L, Zhu Y, Tariot PN. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease. J Am Geriatr Soc. 2004. 52:1070–1076.

43. Wilcock GK, Lilienfeld S, GFaens E. Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomized controlled trial. BMJ. 2000. 321:1445–1449.

44. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, ZAhang R, Haglund A, Subbiah P. Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001. 57:489–495.

45. Grossberg G, Meng X, Olin JT. Impact of Rivastigmine Patch and Capsules on Activities of Daily Living in Alzheimer's Disease. Am J Alzheimers Dis Other Demen. 2011. 26:65–71.

46. Alva G, Grossberg GT, Schmitt FA, Meng X, Olin JT. Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. Int J Geriatr Psychiatry. 2011. 04. 26:356–363.

47. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin. 2005. 21:1317–1327.